acarbose/orlistat (EMP16) / Empros Pharma 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
4 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
acarbose/orlistat (EMP16) / Empros Pharma
2019-004545-32: Lean Efficacy Phase IIa Proof of concept trial (LEAAP). A multi-centre, double-blind, placebo controlled, randomised study in overweight and obese patients during twenty-six weeks, investigating the effect of EMP16-02 on body weight, safety and clinical biomarkers

Not yet recruiting
2
156
Europe
EMP16-02 120/40, EMP16-02 150/50, Capsule
Empros Pharma AB, Empros Pharma AB
Obesity Fetma, Obesity Fetma, Body processes [G] - Metabolic Phenomena [G03]
 
 
2022-003320-40: A 26-week, double-blind, randomized study in participants with overweight or obesity investigating the added contribution of acarbose in EMP16 on efficacy, safety and tolerability

Not yet recruiting
2
320
Europe
EMP16, MR orlistat, Capsule, Xenical®, Alli®
Empros Pharma AB, Empros Pharma AB
Obesity Fetma, obesity Fetma, Body processes [G] - Metabolic Phenomena [G03]
 
 
NCT05934110 / 2022-003320-40: Study Exploring the Supportive Effect of Acarbose in Weight Management

Active, not recruiting
2
320
Europe
EMP16-120/40, MR orlistat 120 mg, Conventional orlistat 120 mg,, Xenical, EMP16-60/20, Placebo
Empros Pharma AB, CTC Clinical Trial Consultants AB
Overweight or Obesity
11/23
03/24
NCT06013163: A Phase 1 Study to Evaluate EMP22 PD and EMP16 PK Versus Xenical® in Healthy Volunteers

Recruiting
1
20
Europe
Xenical® vs EMP 22, Part I, EMP 22 vs Xenical®, EMP 16 vs Xenical®, Part II
Empros Pharma AB, CTC Clinical Trial Consultants AB
Overweight or Obesity
12/24
12/24

Download Options